Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095329 · ClinicalTrials.gov registry record · Phase 1
Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00095329 is a Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 14 participants.
The verdict
NCT00095329, a Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of the drug sirolimus in patients with multiple sclerosis (MS) who have failed other treatments.
Interventions
- BIOLOGICAL sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095329
The ClinicalTrials.gov registry entry for NCT00095329 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sirolimus is the first listed.
NCT00095329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095329 about?
NCT00095329 is a clinical study titled "Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor". The purpose of this study is to determine the safety and tolerability of the drug sirolimus in patients with multiple sclerosis (MS) who have failed other treatments.
What is the current status of trial NCT00095329?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2003-05. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00095329?
The interventions under investigation include: sirolimus (BIOLOGICAL).
Who is sponsoring clinical trial NCT00095329?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.